What is minimal residual disease in PNH?

May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ... ALL prescribers and dispensing sites for ULTOMIRIS or SOLIRIS MUST be certified in the new, combined ULTOMIRIS and SOLIRIS REMS. You can certify here, or; You ... Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... Oct 8, 2020 ... This guide is an educational resource to help patients and their caregivers understand health insurance coverage of SOLIRIS® (eculizumab). Learn ... Mar 21, 2025 ... Eculizumab Biosimilars in PNH: Working Towards Broader Patient Access ... Eculizumab was the first drug approved for the treatment of complement- ... Oct 24, 2017 ... The US Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti- ... Indicated for paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Doses 1-4: 600 mg IV qWeek for first 4 weeks, followed by Dose 5: 900 mg IV 1 week ... Feb 12, 2025 ... These studies suggest that eculizumab and ravulizumab are safe and effective treatments for people with AQP4-Ab+ NMOSD. Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data.